DURHAM – Durham-based Chimerix, Inc. announced two procurement agreements last week worth upwards of $34 million.
In a statement, the biopharmaceutical company noted it had signed a $9.3 million agreement with third party outside of North America.
And in a second statement, the company announced a $25.3 million agreement with Public Health Agency of Chimerix.
The contracts are for TEMBEXA® (brincidofovir), which the company describes as a “medical countermeasure approved for smallpox by the U.S. Food and Drug Administration (FDA) in June 2021.”
Earlier this year, the company signed an agreement with Emergent worth up to $325 million plus royalties. The deal is yet to close, and there are several conditions required in order for the transaction to be completed.
Durham biopharma sells rights to smallpox countermeasure for up to $337M
“This second international procurement contract highlights TEMBEXA’s important role as a medical countermeasure and the need to have these types of medicines in strategic stockpiles for all age groups,” said Mike Sherman, Chief Executive Officer of Chimerix in one of the statements.
“With this new procurement, we are still on track to deliver the expected obligations associated with a potential U.S. Biomedical Advanced Research and Development Authority (BARDA) contract and initial delivery into the U.S. Strategic National Stockpile later this year,” added Sherman.
Here’s the back story behind a $100M fund raiser for Chimerix: A growing oncology pipeline
